Shivanee Nakum1, Andrea E Cavanna2. 1. College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom. 2. College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Neuropsychiatry, Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, United Kingdom; School of Life and Health Sciences, Aston University, Birmingham, United Kingdom; Sobell Department of Motor Neuroscience and Movement Disorders, University College London and Institute of Neurology, London, United Kingdom. Electronic address: a.cavanna@ion.ucl.ac.uk.
Abstract
INTRODUCTION: A range of impulse control disorders have been identified as possible behavioural effects of brain dopamine replacement therapy (DRT) in patients with Parkinson's disease (PD). Among the behavioural problems associated with dysregulation of dopaminergic pathways underlying reward processing, hypersexuality carries significant social and legal repercussions, in addition to embarrassment for the patient with PD and his/her family. The present article evaluates the prevalence and characteristics of hypersexuality in the context of PD, focusing on the best available evidence. METHODS: We conducted a systematic literature review according to the Prisma guidelines on large-scale epidemiological studies (n > 250) assessing hypersexuality in patients with PD treated with DRT. RESULTS: Our systematic literature review identified 10 relevant studies characterised by medium-to-large sample sizes (n = 268-3090). Average lifetime prevalence of hypersexuality in patients with PD on DRT was found to be 2.7% (7.4% in patients on dopamine agonists). In general, hypersexuality was associated with male gender and higher doses of dopamine agonists. Other clinically relevant associations included younger age, earlier PD onset and history of behavioural symptoms prior to dopamine agonist use. CONCLUSION: Hypersexuality is not rare in patients with PD treated with DRT, particularly in those on dopamine agonists. These findings indicate that PD specialists should regularly screen and monitor for hypersexuality, paying particular attention to younger male patients, with an early PD onset and previous history of behavioural problems.
INTRODUCTION: A range of impulse control disorders have been identified as possible behavioural effects of brain dopamine replacement therapy (DRT) in patients with Parkinson's disease (PD). Among the behavioural problems associated with dysregulation of dopaminergic pathways underlying reward processing, hypersexuality carries significant social and legal repercussions, in addition to embarrassment for the patient with PD and his/her family. The present article evaluates the prevalence and characteristics of hypersexuality in the context of PD, focusing on the best available evidence. METHODS: We conducted a systematic literature review according to the Prisma guidelines on large-scale epidemiological studies (n > 250) assessing hypersexuality in patients with PD treated with DRT. RESULTS: Our systematic literature review identified 10 relevant studies characterised by medium-to-large sample sizes (n = 268-3090). Average lifetime prevalence of hypersexuality in patients with PD on DRT was found to be 2.7% (7.4% in patients on dopamine agonists). In general, hypersexuality was associated with male gender and higher doses of dopamine agonists. Other clinically relevant associations included younger age, earlier PD onset and history of behavioural symptoms prior to dopamine agonist use. CONCLUSION: Hypersexuality is not rare in patients with PD treated with DRT, particularly in those on dopamine agonists. These findings indicate that PD specialists should regularly screen and monitor for hypersexuality, paying particular attention to younger male patients, with an early PD onset and previous history of behavioural problems.
Authors: Hendrik Theis; Catharina Probst; Anna Campabadal; Katharina S Goerlich; Oliver Granert; Stephan Wolff; Karsten Witt; Günther Deuschl; Thilo van Eimeren Journal: Exp Brain Res Date: 2022-06-28 Impact factor: 2.064
Authors: E Limoncin; G Ciocca; G Castellini; A Sansone; F Cavalieri; F Cavallo; T Cocchiaro; V Ricca; G di Lorenzo; A Rossi; A D Fisher; V Rochira; G Corona; E A Jannini Journal: J Endocrinol Invest Date: 2022-05-09 Impact factor: 5.467
Authors: Petra J M van Hees; Anton A van der Plas; Gaby F van Ek; Hein Putter; Brenda L Den Oudsten; Marjolein E M den Ouden; Henk W Elzevier Journal: J Neural Transm (Vienna) Date: 2016-11-24 Impact factor: 3.575
Authors: Ji Hyun Choi; Jong Min Kim; Hee Kyung Yang; Hyo Jung Lee; Cheol Min Shin; Seong Jin Jeong; Won Seok Kim; Ji Won Han; In Young Yoon; Yoo Sung Song; Yun Jung Bae Journal: J Korean Med Sci Date: 2020-07-20 Impact factor: 2.153